Antioxidant therapy in idiopathic pulmonary fibrosis: Hope is kindled

European Respiratory Journal

Volumn 27, Issue 4, 2006, Pages 664-666

  Wells, A U ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PLACEBO; PREDNISOLONE;

BONE MARROW TOXICITY; CLINICAL RESEARCH; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DRUG MEGADOSE; DRUG POTENTIATION; EDITORIAL; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG BIOPSY; LUNG FIBROSIS; LUNG TOXICITY; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; RESEARCH SUBJECT; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION;

ACETYLCYSTEINE; ANTIOXIDANTS; AZATHIOPRINE; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; PREDNISOLONE; PULMONARY FIBROSIS;

EID: 33745926700     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00010006     Document Type: Editorial

References (13)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Collard HR, King TE Jr. Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids. Am J Med 2001; 110: 326-328.
3. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242.
4. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999; 159: 1061-1069.
5. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113: 396-400.
6. Raghu G, Brown KK, Bradford WZ, Starko K, Noble Pw, Schwarts DA. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-133.
7. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2285-2287.
8. Shah NR, Noble P, Jackson RM, et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 167-174.
9. Raghu G, Depaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
10. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
11. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
12. Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005; 128: 203-206.
13. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005; 26: 693-702.